Reports Q1 revenue $37.2M, consensus $36M. “We are off to a strong start in 2024. Market demand is stabilizing, and we expect to see continued improvement over the course of the year. We have taken meaningful steps to reduce our expense base and our adjusted EBITDA improved significantly to a loss of less than $4 million,” said Juan Jose Chacon-Quiros, Chief Executive Officer. “Over the past several months, we launched Motiva implants in China as well as our Flora tissue expander in the United States. The number of clinics offering Mia around the world is growing and we are seeing strong evidence that Mia is opening an entirely new and market expanding category in breast aesthetics.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESTA:
- Establishment Labs price target raised to $62 from $53 at BTIG
- Establishment Labs price target raised to $60 from $49 at Citi
- Establishment Labs says FDA schedules preapproval inspection for Motiva facility
- Establishment Labs participates in a conference call with JPMorgan
- Establishment Labs price target raised to $65 from $50 at Mizuho